Table 4 Secondary outcomes of meta-analyses in included randomized controlled trials.
Variables | Studies (n) | Patients (n) | Overall Effect | Heterogeneity P Value (I2) | Model | |
|---|---|---|---|---|---|---|
P value | MD/OR (95% CI) | |||||
Clinical outcomes | ||||||
 ROM | ||||||
24 h | 4 | 355 | <0.0001 * | 5.12 (2.80, 7.45) | 0.35 (9%) | F |
48 h | 4 | 257 | 0.001 * | 8.39 (3.35, 13.44) | 0.08 (60%) | R |
48 h * | 3 | 197 | <0.0001 * | 11.10 (6.80, 15.40) | 0.84 (0%) | F |
72 h | 3 | 197 | <0.0001 * | 9.23 (6.45, 12.01) | 0.30 (8%) | F |
 Patients able to perform TUG test | ||||||
<24 h | 3 | 226 | <0.0001 * | 23.14 (5.33, 100.37) | 0.91 (0%) | F |
48 h | 2 | 121 | 0.58 | 1.19 (0.06, 24.85) | 0.06 (72%) | R |
72 h | 2 | 121 | 0.09 | 0.37 (0.12, 1.17) | 0.45 (0%) | F |
 Patients satisfaction | ||||||
<24 h | 3 | 194 | 0.28 | 0.13 (−0.11, 0.37) | 0.77 (0%) | F |
48 h | 3 | 194 | 0.79 | −0.15 (−1.29, 0.98) | 0.02 (73%) | R |
72 h | 2 | 101 | 0.91 | 0.11 (−1.75, 1.97) | 0.02 (82%) | R |
 TUG test | 5 | 272 | 0.08 | −35.89 (−76.35, 4.58) | <0.0001 (98%) | R |
 TUG test * | 4 | 174 | 0.09 | −12.19 (−26.47, 2.09) | 0.15 (44%) | F |
 The time to SLR | 3 | 195 | 0.13 | −2.19 (−5.02, 0.65) | 0.05 (75%) | R |
 Tourniquet time | 3 | 188 | 0.66 | −1.19 (−6.39, 4.02) | 0.62 (0%) | F |
 Hospital stay | 3 | 271 | 0.18 | −0.86 (−2.11, 0.40) | 0.02 (82%) | R |
 Opioid consumption | 5 | 332 | 0.62 | −2.93 (−14.47, 8.61) | 0.007 (72%) | R |
 Opioid consumption* | 4 | 283 | 0.39 | 2.56 (−3.24, 8.37) | 0.76 (0%) | F |
Complications | ||||||
 Falls risk | 7 | 471 | 0.003 * | 0.30 (0.13, 0.67) | 0.75 (0%) | F |
 Nausea or vomiting | 4 | 309 | 0.98 | 1.01 (0.42, 2.45) | 0.88 (0%) | F |
 Pruritus | 3 | 221 | 0.69 | 1.15 (0.57, 2.32) | 0.94 (0%) | F |
 Urinary retention | 3 | 229 | 0.63 | 1.22 (0.54, 2.74) | 0.97 (0%) | F |
